Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Summary of Significant Accounting Policies (Details Textual)

v3.8.0.1
Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2017
Sep. 30, 2016
Mar. 31, 2015
Mar. 31, 2017
Sep. 30, 2017
Dec. 31, 2016
Derivative Liability         $ 63,000 $ 63,000
Notes Payable, Fair Value Disclosure         $ 0  
Accounting Standards Update 2016-09 [Member]            
Operating Loss Carryforwards           $ 15,300,000
Nonsoftware License Arrangement [Member] | SpePharm AG [Member]            
Deferred Revenue, Additions     $ 2,000,000      
Deferred Revenue, Recognition Period     2 years      
Deferred Revenue, Revenue Recognized   $ 417,000        
Series NN Warrants [Member]            
Class of Warrant or Right, Term 5 years          
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.50     $ 1.50    
Series NN Warrants [Member] | Cardinal Health 414 [Member]            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 10,000,000     10,000,000    
Class of Warrant or Right, Grants in Period, Estimated Fair Value       $ 3,300,000    
Series NN Warrants [Member] | UCSD [Member]            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,000,000     1,000,000 1,000,000  
Class of Warrant or Right, Grants in Period, Estimated Fair Value       $ 334,000 $ 334,000